Gene editing: Towards the third generation of adoptive T-cell transfer therapies
Open Access
- 14 June 2019
- journal article
- review article
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 1, 19-26
Abstract
No abstract availableKeywords
Funding Information
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (R35 CA197633, P01 CA168585)
- Ressler Family Fund
This publication has 113 references indexed in Scilit:
- RNA-Guided Human Genome Engineering via Cas9Science, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood, 2010
- Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated TumorCancer Research, 2010
- Intracellular DNA recognitionNature Reviews Immunology, 2010
- Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulationBlood, 2009
- Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivityGene Therapy, 2009
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006